Gain Therapeutics GANX Stock
Gain Therapeutics Price Chart
Gain Therapeutics GANX Financial and Trading Overview
| Gain Therapeutics stock price | 1.9 USD |
| Previous Close | 4.96 USD |
| Open | 4.9 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1000 |
| Day's Range | 4.84 - 4.95 USD |
| 52 Week Range | 2.8 - 6.19 USD |
| Volume | 11.96K USD |
| Avg. Volume | 77.29K USD |
| Market Cap | 60.04M USD |
| Beta (5Y Monthly) | 0.367549 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.89 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9 USD |
GANX Valuation Measures
| Enterprise Value | 44.54M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.2466667 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 399.52393 |
| Price/Book (mrq) | 3.8897762 |
| Enterprise Value/Revenue | 296.385 |
| Enterprise Value/EBITDA | -2.268 |
Trading Information
Gain Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.367549 |
| 52-Week Change | 33.79% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.19 USD |
| 52 Week Low | 2.8 USD |
| 50-Day Moving Average | 4.94 USD |
| 200-Day Moving Average | 3.94 USD |
GANX Share Statistics
| Avg. Volume (3 month) | 77.29K USD |
| Avg. Daily Volume (10-Days) | 44.72K USD |
| Shares Outstanding | 12.33M |
| Float | 9.8M |
| Short Ratio | 0.74 |
| % Held by Insiders | 24.34% |
| % Held by Institutions | 10.58% |
| Shares Short | 44.26K |
| Short % of Float | 0.38% |
| Short % of Shares Outstanding | 0.36% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -13120.90% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -41.83% |
| Return on Equity (ttm) | -82.84% |
Income Statement
| Revenue (ttm) | 150.28K USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | 47.00% |
| Gross Profit (ttm) | -7660886 USD |
| EBITDA | -19643152 USD |
| Net Income Avi to Common (ttm) | -19455414 USD |
| Diluted EPS (ttm) | -1.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 17.82M USD |
| Total Cash Per Share (mrq) | 1.45 USD |
| Total Debt (mrq) | 1.21M USD |
| Total Debt/Equity (mrq) | 7.97 USD |
| Current Ratio (mrq) | 3.748 |
| Book Value Per Share (mrq) | 1.252 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16462163 USD |
| Levered Free Cash Flow (ttm) | -9133083 USD |
Profile of Gain Therapeutics
| Country | United States |
| State | MD |
| City | Bethesda |
| Address | 4800 Montgomery Lane |
| ZIP | 20814 |
| Phone | 301 500 1556 |
| Website | https://www.gaintherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 28 |
Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Q&A For Gain Therapeutics Stock
What is a current GANX stock price?
Gain Therapeutics GANX stock price today per share is 1.9 USD.
How to purchase Gain Therapeutics stock?
You can buy GANX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gain Therapeutics?
The stock symbol or ticker of Gain Therapeutics is GANX.
Which industry does the Gain Therapeutics company belong to?
The Gain Therapeutics industry is Biotechnology.
How many shares does Gain Therapeutics have in circulation?
The max supply of Gain Therapeutics shares is 27.79M.
What is Gain Therapeutics Price to Earnings Ratio (PE Ratio)?
Gain Therapeutics PE Ratio is now.
What was Gain Therapeutics earnings per share over the trailing 12 months (TTM)?
Gain Therapeutics EPS is -0.89 USD over the trailing 12 months.
Which sector does the Gain Therapeutics company belong to?
The Gain Therapeutics sector is Healthcare.
Gain Therapeutics GANX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17328.57 USD — |
-0.31
|
3.45B USD — | 17297.61 USD — | 17467.35 USD — | — - | 3.45B USD — |
| NASDAQ Global Market Composite NQGM | 1869.23 USD — |
+1.6
|
— — | 1846.41 USD — | 1871.93 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 932.99 USD — |
+1.03
|
— — | 927.87 USD — | 934.26 USD — | — - | — — |
- {{ link.label }} {{link}}